Navigation Links
European Medicines Agency (EMEA) Recommends Herceptin For Early Stage Breast Cancer

The European Medicines Agency (EMEA) has recommended the use of breast cancer drug Herceptin in early stages of the cancer in a record 27 days review//. A license for the drug is to be issued in three months time.

The National Institute of Health and Clinical Excellence in the UK will decide now if Herceptin can be recommended in the NHS. The drug, which costs £20,000 a year, is already being fast tracked by NICE. "We will be able to issue national guidance to the NHS on the use of Herceptin within weeks of the drug being licensed for safety by the EMEA," said Andrew Dillon, NICE chief executive.

Herceptin is already licensed for use in advanced breast cancer. But some trials showed that it is useful in early stages as well and the UK has seen a number of women drag NHS trusts to court over refusal to fund the drug. Health Secretary Patricia Hewitt had said last October that NHS bodies must not refuse the drug, if the doctors had recommended it.

But NHS trusts continued to refuse the drug, forcing patients to seek refuge in court. Ann Marie Rogers of Swindon, Wiltshire won a case earlier this month ruling forcing her local primary care trust to fund Herceptin. The news of Herceptin's approval by the EMEA was welcomed by charity Breakthrough Breast Cancer, "Not only does this confirm the drug's importance, it should also help reassure those who may have previously doubted its effectiveness and safety," said Chief executive Jeremy Hughes. "We hope that in light of today's decision, any PCT still wavering about prescribing Herceptin, should now have the confidence to make it available to all for whom it is recommended."


'"/>




Page: 1

Related medicine news :

1. Lung Cancer Deaths Declining In Men But Not Women In European Countries
2. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
3. European Countries To Fund $4 Billion For Vaccination For Poor Children’
4. Nanotechnology Revolution To Be Spearheaded By European Union
5. Detection of Weak strains of bird flu virus – Target of European Unio
6. Europe On High Bird Flu Alert: European Commission
7. Slovenia, Bulgaria, Greece Face Bird Flu Threat: European Union
8. Heart Brakes: Hearts in European Union Invite Health Attention
9. European Union: Poultry producers Need Aid to Survive Bird flu crisis
10. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
11. Control And Prevention Of Three Diseases To Be Discussed: European Commission
Post Your Comments:
(Date:8/28/2008)...conventional therapy, study found , , TH... a treadmill improves brain function and fitness f...ugh the usual rehabilitation program, a new study ...ts have," said study researcher Dr. Andreas Luft, ...itation at the University of Zurich in Switzerland...
(Date:8/28/2008)...al efforts of the Maryland Medicaid contract, HAR...ional medical,management firm, appointed Lenaye La...or. Dr. Lawyer will oversee all clinical aspects o...unt Valley, Maryland Harrisburg,office., "Dr. Law...yland," said,Alice Stollenwerk Petrulis, MD, FACP,...
(Date:8/28/2008)...d physical, especially for the impaired, study say... -- A new study says that 13 percent of American s...buse. , The University of Chicago researchers ..., being taken advantage of financially (3.5 percen...o found that seniors with physical impairments wer...
(Date:8/28/2008)...ding dermatology company serves growing profession... Palo Alto, CA (PRWEB) August 28, 2008 -...l firm, today announced that together with Mustang...ding a Series A round of financing for Profex.Inc....vested $15.5 million in the round. Profex, a leadi...
Breaking Medicine News(10 mins):Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3
...ting away a tumor in the kidney appears to be a pr... frequency ablation is done by placing a special n...ough the electrode // to heat the tumor tissue and...ients not only respond to the treatment but also d...
...ucoma occurs when the fluid that flows in and out ... pressure inside the eye. A new study shows press...nt // the onset of glaucoma in nearly 50 percent ...the disease. According to the article, glaucoma is...
...ple with a serious heart condition called nonische...rvival if they have a device called a cardioverter...rchers, assigned about 460 patients with severe ca...treatment, with drugs like ACE inhibitors and beta...
...inning in 2000, doctors began distributing a new v... 1998 and 2002 annual incidence rates for invasive...creased among both // blacks and whites. In 2002, ...0 fewer cases occurred among blacks compared with ...
Other Medicine News:
(Date:8/28/2008)..., Austria, Aug. 28 /- Intercell AG (V...rck & Co., Inc. has initiated a Phase II,clinical ...prevention of,Staphylococcus aureus (S. aureus) in...ntrolled study aims to evaluate the safety and imm...ith end-stage kidney disease on,hemodialysis. This...
(Date:8/27/2008)...ing Research Team Makes Crucial Breakthrough in Ba...inson,s Disease, CHICAGO, Aug. 27 /-...y announced that scientists at The University of N...battle to slow or prevent the onset,of a very comm... researchers have genetically produced the first e...
(Date:8/26/2008)...mpany to present data from landmark SYNTAX clinica...Call/ -- Boston Scientific,Corporation (NYSE: BSX...ajor,events and press announcements at the Europea...from August 30 to September 3 in Munich, Germany.,... the SYNTAX trial,which compares percutaneous cor...
(Date:8/26/2008)..., Mass., Aug. 26 /- Cambridge Researc...ase of the Maestro(TM) EX In,Vivo Imaging System. ...,FLEX technology and becomes the entry-level instr... (Photo: http://www.newscom.com/cgi-bin/prnh/200...gnificant advancement of CRi,s unique,solid-state ...
Breaking Medicine Technology:Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price 2BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 1BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 2BioMed Realty Trust Announces Exercise of Over Allotment Option for Common Stock 4777 3Gene Variant Boosts Risk for Stress Related Ischemia 17446 1Gene Variant Boosts Risk for Stress Related Ischemia 17446 2OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival 17442 1OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival 17442 2Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 1Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 2Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 17438 3
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens.
...nd probe system used together to quantify gene exp... system is a sandwich nucleic acid hybridization a...tion and quantification, by amplifying the reporte...nched DNA allows immediate quantification of targe...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits.
Clearview Simplify D-dimer test kits
Medicine Products: